Evidence map›Paper›PMID 41565650›Full record

ArticleNature communications2026

An ultra-long-acting dimeric bictegravir prodrug defined by a short pharmacokinetic tail.

Mohammad Ullah Nayan, Brady Sillman, Srijanee Das, Brandon W Hanson, Ashrafi Sultana, Nam Thai Hoang Le, Suyash Deodhar, Bhoomika Gowda, Prasanta K Dash, Satish Agrawal and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Mohammad Ullah NayanDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA.
Brady SillmanDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA.ORCID http://orcid.org/0000-0002-7123-3034
Srijanee DasDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA.ORCID http://orcid.org/0000-0002-2792-0718
Brandon W HansonDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA.ORCID http://orcid.org/0009-0007-0740-1201
Ashrafi SultanaDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA.ORCID http://orcid.org/0000-0003-2653-6834
Nam Thai Hoang LeDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA.
Suyash DeodharDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA.
Bhoomika GowdaDepartment of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA.
Prasanta K DashDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA.ORCID http://orcid.org/0000-0002-8250-2359
Satish AgrawalDepartment of Pharmacy Sciences, Creighton University, Omaha, NE, USA.
Alekha K DashDepartment of Pharmacy Sciences, Creighton University, Omaha, NE, USA.
Samuel M CohenDepartment of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, Omaha, NE, USA.ORCID http://orcid.org/0000-0002-5047-0962
Chen ZhangDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA.ORCID http://orcid.org/0000-0002-0785-1292
Howard E GendelmanDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA.ORCID http://orcid.org/0000-0002-7831-0370
Benson EdagwaDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA. benson.edagwa@unmc.edu.ORCID http://orcid.org/0000-0003-1484-9331

Funding

Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID) R01AI145542, R01AI158160 and R01AI163042
6 · The paper itself

Abstract

Ultra-long-acting (ULA) antiretroviral parenteral formulations, with low injection volumes, high resistance barriers, and short pharmacokinetic (PK) tails, can transform HIV-1 therapeutics. Here, we converted bictegravir (BIC), a potent daily oral antiretroviral drug, into monomeric and homodimeric ester prodrugs. The homodimeric prodrug nanosuspension, NMXBIC, shows sustained plasma BIC levels > 16 times the protein-adjusted 95% inhibitory concentration (PA-IC

Indexed as

Anti-HIV AgentsProdrugsAnimalsDiketopiperazinesHIV-1HumansMaleRabbitsRatsRats, Sprague-DawleyAnti-HIV AgentsDiketopiperazinesProdrugs

Identifiers

PMID41565650
PMCPMC12916993

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.